FDA Delays Decision on Eli Lilly's Alzheimer's Drug Donanemab
Originally Published 1 year ago — by Financial Times
The US regulator has postponed its decision on Eli Lilly's experimental Alzheimer's drug, donanemab, citing the need for more time to review additional data. The drug has shown promise in slowing the progression of the disease, and the delay in the decision is seen as a setback for the company's efforts to bring a new treatment to market.